Introduction {#sec1-0300060515593765}
============

Vitamin D is an essential hormone obtained from the diet (10--20%) or skin synthesis. It has a classical function in maintaining calcium and phosphate homeostasis, but also an extensive role in maintaining immunity, vascular function,^[@bibr1-0300060515593765]^ cardiomyocyte health, inflammation,^[@bibr2-0300060515593765]^ insulin resistance^[@bibr3-0300060515593765]^ and in lowering the urinary albumin concentration in patients with chronic kidney disease.^[@bibr4-0300060515593765]^ Vitamin D can be hydroxylated into 25-hydroxyvitamin D (25\[OH\]D) in the liver, then converted to its active form by 1-hydroxylation in the renal proximal tubules. Renal dysfunction can influence serum 25(OH)D levels, and studies have confirmed the occurrence of low serum 25(OH)D levels in patients with chronic kidney disease.^[@bibr5-0300060515593765],[@bibr6-0300060515593765]^ Low vitamin D levels are suggested to be associated with different impaired glucose metabolism states including diabetes mellitus.^[@bibr7-0300060515593765]^ Diabetic nephropathy is a major microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease worldwide.^[@bibr8-0300060515593765]^ Oral paricalcitol has been shown to reduce albuminuria and inflammation in chronic kidney disease,^[@bibr9-0300060515593765]^ and animal studies have shown that calcitriol supplement can reduce albuminuria in mice with diabetic nephropathy.^[@bibr10-0300060515593765]^

Vitamin D deficiency has been reported mainly in patients with chronic kidney disease or in patients with diabetes mellitus who have normal renal function.^[@bibr7-0300060515593765],[@bibr11-0300060515593765]^ Few studies have analysed vitamin D metabolic levels in patients with diabetic nephropathy. Furthermore, risk factors for vitamin D deficiency in patients with diabetic nephropathy remain unclear. The present study evaluated the prevalence of vitamin D deficiency in patients with diabetic nephropathy and determined their correlation with clinicopathological features and possible risk factors for vitamin D deficiency.

Patients and methods {#sec2-0300060515593765}
====================

Study population {#sec3-0300060515593765}
----------------

Patients with different stages of diabetic nephropathy from the Department of Endocrinology, Nephrology, and Geriatrics of Qilu Hospital, Shandong University, Jinan, China and Zhangqiu City People's Hospital, Jinan, China were sequentially enrolled between May 2012 and July 2012, to eliminate the effect of season and geographical area. Data were reviewed retrospectively.

All patients with diabetic nephropathy who met the following inclusion and exclusion criteria were enrolled. Inclusion criteria: patients diagnosed with type 2 diabetes mellitus (including patients with intermittent microalbuminuria (i.e. very mild kidney injury), persistent urinary microalbumin albumin excretion rate \[AER\] of 30--300 mg/24 h, or macroalbuminuria \[AER \> 300 mg/24 h\].^[@bibr12-0300060515593765]^ Exclusion criteria: patients \<18 years of age; patients with end-stage renal disease not caused by diabetes mellitus and who required renal replacement therapy; patients with an active infection, severe cardiovascular disease, cancer, liver disease, current pregnancy, gallbladder problem or gastrointestinal disorder;^[@bibr13-0300060515593765]^ patients who had used mineral oil products and daily multivitamins (i.e., vitamin D) for ≥4 weeks prior to the screening visit, or regularly used antacids, used cortisone or other steroids, weight-loss drugs, phenobarbital or acyeterion;^[@bibr14-0300060515593765]^ patients whose estimated glomerular filtration rate (eGFR) was\<10 ml/min/1.73 m^2^ and who required dialysis; patients using renin-angiotensin system inhibitors (as these can reduce albuminuria).^[@bibr14-0300060515593765]^ Healthy controls were randomly enrolled from people living in the same area as the patients with kidney injury, attending the Physical Examination Centre of Qilu Hospital for health examination; control subjects were age- and sex-matched to the patients, and also matched the exclusion criteria. Diabetic nephropathy stage was based on the 2011 American Diabetes Association guidelines:^[@bibr12-0300060515593765]^ Stage I, GFR is significantly increased; Stage II, urinary albumin excretion rate is mainly normal, but may increase intermittently (such as following exercise, or stress), and GFR may be slightly increased; Stage III, urinary albumin excretion rate is 20--200 µg/min, GFR remains normal or increased; Stage IV, urinary albumin excretion rate is \>200 µg/min, and GFR is decreased; Stage V, urinary albumin excretion rate is decreased and serum creatinine is increased.

The study was approved by the Ethics Committee of Qilu and Zhangqiu City People's Hospitals, and written informed consent was obtained from each participant.

Clinical examination {#sec4-0300060515593765}
--------------------

Body mass index (BMI), waist hip ratio (WHR), creatinine clearance rate (Ccr), and eGFR were measured and calculated for each participant. Blood pressure was measured in a sitting position following 10 min rest using a mercury sphygmomanometer. Standard ophthalmological evaluation was performed in each patient to identify nonproliferative or proliferative diabetic retinopathy. Peripheral neuropathy was identified using an electromyogram.

Laboratory parameters {#sec5-0300060515593765}
---------------------

To measure the standard range of biochemical parameters that would be tested for in patients with diabetes mellitus, using standard methods, fasting blood specimens (∼5 ml) were collected into tubes containing separation gel coagulant or ethylenediaminetetra-acetic acid (for glycosylated haemoglobin \[HbA~1c~\] analysis), then centrifuged at 2 390 ***g*** at room temperature for 5 min and stored at −20℃ prior to use. All participants underwent a 24 h urinary albumin excretion test by measuring urinary albumin (N antiserum to human albumin kit; BN prospec, Siemens, Germany) and urinary creatinine (Creatinine Plus version 2 kit; Cobas c701, Roche, Germany) according to the manufacturer's instructions. Serum 25(OH)D levels were measured using high-pressure liquid chromatography, as described previously.^[@bibr15-0300060515593765]^ A serum 25(OH)D level\<15 ng/ml was defined as deficient.

Sample size {#sec6-0300060515593765}
-----------

The sample size of this cohort study was selected according to the following four aspects:^[@bibr16-0300060515593765]^ First, morbidity or mortality of the nonexposure population (the required sample size is larger when it is closer to 0.5); secondly, morbidity or mortality of the exposure population; thirdly, the required significance level; fourthly, the required study power. The prevalence of vitamin D deficiency and insufficiency is ∼69.0% and ∼24.4% of the population in Beijing and Shanghai, China, respectively.^[@bibr17-0300060515593765]^ The present desired significance level was *P* \< 0.05, and the study power was \>0.75, thus, the overall required sample size was calculated to be ∼210 cases to be able to detect statistical significance.

Statistical analyses {#sec7-0300060515593765}
--------------------

All data were presented as mean* ± *SD. Statistical analyses were performed using SPSS® software, version 19.0 (SPSS, Inc., Chicago, IL, USA) by an expert statistician. Univariate conditional logistic regression analysis was used to investigate significant factors associated with 25(OH)D deficiency, and to rule out confounding factors. Multivariate conditional logistic regression was used to determine independent risk factors and prognostic factors) for 25(OH)D deficiency. A *P* value \< 0.05 was considered to be statistically significant, unless specifically explained.

Results {#sec8-0300060515593765}
=======

A total of 240 patients with different diabetic nephropathy stages (*n* = 60 per group) and 60 healthy controls were included in the present study.

Clinical characteristics {#sec9-0300060515593765}
------------------------

Basic clinical characteristics of patients with diabetic nephropathy and normal controls are shown in [Table 1](#table1-0300060515593765){ref-type="table"}. Patients with diabetic nephropathy stage V were significantly older than the control group and had a longer history of diabetes than patients with stages III or IV diabetic nephropathy (*P \< *0.05). Patients with diabetic nephropathy stages IV and V had higher BMIs versus controls and patients with diabetic nephropathy stage I/II (*P \< *0.05). All diabetic nephropathy groups had higher systolic blood pressure (SBP) than controls, and SBP showed a trend to increase as diabetic nephropathy progressed ([Table 1](#table1-0300060515593765){ref-type="table"}). AER in patients with diabetic nephropathy stage IV was significantly different from controls and patients with diabetic nephropathy stage I/II or stage III (*P \< *0.05), and AER in patients with diabetic nephropathy stage V was significantly higher than all other groups (all *P \< *0.05). Fasting blood glucose and HbA~1c~ were significantly higher in all diabetic nephropathy groups versus controls and appeared to plateau in patients with diabetic nephropathy stage IV. Haemoglobin levels were significantly lower in patients with diabetic nephropathy stages IV and V versus controls, and significantly lower in patients with stage V versus stage IV diabetic nephropathy (all *P \< *0.05). Serum albumin showed a tendency to decrease with diabetic nephropathy progression, as did Ccr, eGFR,. Blood urea nitrogen (BUN), uric acid and cystatin-C were significantly higher in patients with diabetic nephropathy stage V versus stages I/II and III and controls. Total cholesterol, triglycerides and low-density lipoprotein (LDL) cholesterol in patients with diabetic nephropathy stage V were significantly higher than stages I/II and controls (all *P \< *0.05). Serum calcium levels were significantly lower in patients with diabetic nephropathy stage V versus all other groups (all *P \< *0.05). Table 1.Demographic and clinical characteristics of patients grouped according to stage of diabetic nephropathy (*n* = 240) and healthy controls (*n* = 60).Diabetic nephropathy stageVariableControl groupI/IIIIIIVVParticipants, *n*6060606060Age, years50 ± 757 ± 856 ± 1059 ± 1062 ± 9[\*](#table-fn3-0300060515593765){ref-type="table-fn"}Sex, male/female27/3329/3122/3826/3430/30Diabetes history, years--14.9 ± 4.810.2 ± 4.9^\#^12.4 ± 5.316.0 ± 6.4^Δ&^BMI, kg/m^2^24.1 ± 2.924.5 ± 2.525.7 ± 1.727.1 ± 2.7[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^26.9 ± 2.8[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^WHR0.93 ± 0.060.90 ± 0.140.93 ± 0.100.96 ± 0.090.96 ± 0.09SBP, mmHg120.7 ± 12.0139.4 ± 13.1[\*](#table-fn3-0300060515593765){ref-type="table-fn"}140.1 ± 17.8[\*](#table-fn3-0300060515593765){ref-type="table-fn"}150.1 ± 20.6[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^158.7 ± 18.8[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ^DBP, mmHg76.9 ± 7.678.5 ± 8.881.3 ± 7.583.0 ± 7.679.6 ± 8.3AER, mg/24 h10.5 ± 2.513.2 ± 3.7139.1 ± 53.31231.2 ± 332.2[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ^1799.2 ± 495.7[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^eGFR, ml/min/1.73 m^2^102.5 ± 10.478.3 ± 14.5[\*](#table-fn3-0300060515593765){ref-type="table-fn"}43.1 ± 11.8[\*](#table-fn3-0300060515593765){ref-type="table-fn"}17.9 ± 12.6[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ^13.5 ± 3.1[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^25(OH)D29.43 ± 10.1512.23 ± 4.07[\*](#table-fn3-0300060515593765){ref-type="table-fn"}10.31 ± 3.36[\*](#table-fn3-0300060515593765){ref-type="table-fn"}8.44 ± 2.53[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^7.74 ± 2.90[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^Fasting blood glucose, mmo/l5.18 ± 0.468.47 ± 2.40[\*](#table-fn3-0300060515593765){ref-type="table-fn"}10.40 ± 1.75[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^9.37 ± 3.89[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^Δ^7.36 ± 1.23[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^&^HbA~1c~, %5.0 ± 0.37.8 ± 1.8[\*](#table-fn3-0300060515593765){ref-type="table-fn"}9.4 ± 2.1[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^9.8 ± 2.2[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^9.0 ± 2.2[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^Haemoglobin, g/l135 ± 11130 ± 18128 ± 11112 ± 21[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^81 ± 15[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^Serum albumin, g/l46.0 ± 3.642.8 ± 3.3[\*](#table-fn3-0300060515593765){ref-type="table-fn"}41.3 ± 5.7[\*](#table-fn3-0300060515593765){ref-type="table-fn"}36.9 ± 8.1[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ^33.2 ± 5.8[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^Serum creatinine, µmol/l77.2 ± 15.762.9 ± 11.171.5 ± 17.4114.5 ± 39.0363.3 ± 47.6[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^Ccr, ml/min92.4 ± 18. 8107.5 ± 33.0112.4 ± 32.573.3 ± 25.0[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^29.6 ± 9.6[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^BUN, mmol/l4.64 ± 1.315.08 ± 1.116.00 ± 2.057.64 ± 2.2116.52 ± 4.79[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^Uric acid, umol/l312.4 ± 94.2236.0 ± 57.9[\*](#table-fn3-0300060515593765){ref-type="table-fn"}291.3 ± 78.5294.9 ± 81.0^\#Δ^381.6 ± 133.0[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^Cystatin-C, mg/l0.78 ± 0.120.83 ± 0.190.90 ± 0.181.15 ± 0.39[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ^2.69 ± 0.64[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ^Total cholesterol, mmol/l1.47 ± 1.201.17 ± 0.622.58 ± 0.66[\*](#table-fn3-0300060515593765){ref-type="table-fn"}1.71 ± 0.81[\*](#table-fn3-0300060515593765){ref-type="table-fn"}2.14 ± 0.91[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^Total triglyceride, mmol/l4.74 ± 0.754.85 ± 1.355.19 ± 1.07[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#^4.78 ± 1.176.04 ± 1.17[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^HDL cholesterol, mmol/l1.37 ± 0.351.35 ± 0.281.15 ± 0.22[\*](#table-fn3-0300060515593765){ref-type="table-fn"}1.20 ± 0.531.22 ± 0.28LDL cholesterol, mmol/l2.64 ± 0.693.00 ± 0.90[\*](#table-fn3-0300060515593765){ref-type="table-fn"}3.12 ± 1.00[\*](#table-fn3-0300060515593765){ref-type="table-fn"}2.83 ± 0.97[\*](#table-fn3-0300060515593765){ref-type="table-fn"}3.70 ± 1.56[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#&^Serum Ca, mmol/l2.29 ± 0.102.25 ± 0.122.23 ± 0.14[\*](#table-fn3-0300060515593765){ref-type="table-fn"}2.22 ± 0.18[\*](#table-fn3-0300060515593765){ref-type="table-fn"}2.10 ± 0.19[\*](#table-fn3-0300060515593765){ref-type="table-fn"}^\#Δ&^Serum P, mmol/l1.26 ± 0.181.15 ± 0.191.38 ± 1.121.24 ± 0.201.35 ± 0.35DRP, yes/no0/6020/4032/2841/1949/11DNP, yes/no0/6023/3730/3029/3140/20Smoking, male, yes/no13/1412/1715/718/819/11Drinking, male, yes/no15/1219/108/1414/1216/14[^2][^3][^4]

Low 25(OH)D levels in patients with diabetic nephropathy {#sec10-0300060515593765}
--------------------------------------------------------

Serum 25(OH)D levels were significantly lower in the four diabetic nephropathy groups than in the healthy controls (*P \< *0.05). Furthermore, serum 25(OH)D levels in diabetic nephropathy groups IV and V were significantly lower than in diabetic nephropathy group I/II (*P \< *0.05; [Table 1](#table1-0300060515593765){ref-type="table"} and [Figure 1](#fig1-0300060515593765){ref-type="fig"}). Figure 1.Serum 25-hydroxyvitamin D (25\[OH\]D) levels in patients grouped into different diabetic nephropathy stages. Data presented as mean ± SD; \**P* \< 0.05 versus healthy controls; ^\#^*P* \< 0.05 versus diabetic nephropathy 1--2; NC, healthy controls; CKD, diabetic nephropathy groups (all one-way analysis of variance).

Association between 25(OH) D levels and clinical parameters {#sec11-0300060515593765}
-----------------------------------------------------------

Univariate conditional logistic regression analysis found that serum 25(OH)D levels were significantly associated with age, sex, diabetes history, BMI, SBP, AER, eGFR, fasting blood glucose, HbA~1c~, haemoglobin, serum albumin, Ccr, BUN and proliferative diabetic retinopathy ([Table 2](#table2-0300060515593765){ref-type="table"}). In addition, serum 25(OH)D levels were lower in older, female and obese participants. Significantly more patients with high AER and high glucose levels had low 25(OH)D levels (≤15 ng/ml), and significantly more patients with low serum albumin, mild anaemia, and decreased eGFR and Ccr had low 25(OH)D levels (≤15 ng/ml; [Table 2](#table2-0300060515593765){ref-type="table"}). Other indices such as diabetes history, SBP, serum creatinine, BUN, smoking, drinking, and complicated diabetic neuropathy were considered to be confounding factors ([Table 2](#table2-0300060515593765){ref-type="table"}). Table 2.Univariate conditional logistic regression analysis of significant factors for 25-hydroxyvitamin D (25\[OH\]D) deficiency in patients with diabetic nephropathy (*n* = 240) and healthy controls (*n* = 60).25(OH)D levelFactor \> 15 ng/ml *n = *84; 28*%*≤ 15 ng/ml *n = *216; 72*%*Statistical significanceAge, years \<402978ref 40 -- 604171*P* = 0.003 \>601464*P* \< 0.001Sex, male/female Male5084 Female34132*P* = 0.009Diabetes history, years \<10^[a](#table-fn5-0300060515593765){ref-type="table-fn"}^3771 ≥1047145*P* = 0.020BMI, kg/m^2^ \<20912ref 20 -- 255250NS 26 -- 3013134*P* = 0.002 \>301020*P* \< 0.001WHR \<0.93985 ≥0.945131NSSBP, mmHg \<1406799ref 140 -- 1601767*P* = 0.030 \>160060*P* \< 0.001AER, mg/24 h \<307347ref 30 -- 3001149*P* \< 0.001 \>3000120*P* \< 0.001eGFR, ml/min/1.73 m^2^ \<15060NS 15 -- 30060*P* \< 0.001 31 -- 601149*P* \< 0.001 \>607347refFasting blood glucose, mmol/l \<7.83441ref 7.8 -- 11.147124*P* \< 0.001 \>11.1351*P* \< 0.001HbA~1c~, % \<6.0603ref 6.0 -- 8.02169*P* \< 0.001 \>8.03144*P* \< 0.001Haemoglobin, g/l \<6000 60 -- 90158NS 91 -- 1201490*P* = 0.015 \>1206968refSerum albumin, g/l \<350120 ≥358496*P* \< 0.001Serum creatinine, µmol/l \<9784156 ≥97060NSCcr, ml/min \<800120 ≥808496*P* = 0.010BUN, mmol/l \<2084156 ≥20060*P* = 0.026Uric acid, µmol/l \<48882216 ≥48820NSCystatin-C, mg/l \<1.0979117 ≥1.09599NSTotal cholesterol, mmol/l \<5.9866134 \>5.981882NSTotal triglyceride, mmol/l \<1.769137 ≥1.71579NSHDL cholesterol, mmol/l \<0.94663 ≥0.9478153NSLDL cholesterol, mmol/l \<3.126495 ≥3.1220121NSSerum Ca, mmol/l \<2.254157 ≥2.258059NSSerum P, mmol/l \<1.6178113 ≥1.616103NSDRP, yes/no Yes10122 No7494*P* \< 0.001DNP, yes/no Yes583 No79123NSSmoking, male, yes/no Yes2159 No1836NSDrinking, male, yes/no Yes1950 No2045NS[^5][^6][^7][^8]

Multivariate conditional logistic regression analysis showed that age, BMI, AER, haemoglobin, and HbA~1c~ remained significant as independent prognostic factors for 25(OH)D deficiency, and ([Table 3](#table3-0300060515593765){ref-type="table"}). Table 3.Multivariable conditional logistic regression of significant factors for 25-hydroxyvitamin D (25\[OH\]D) deficiency in study participants.Characteristic25(OH)D  \> 15 ng/ml25(OH)D  ≤ 15 ng/mlOR95% CIStatistical significanceAge, years \>6014640.2970.228, 0.466*P* = 0.008BMI, kg/m^2^ \>25231541.1091.042, 2.176*P* = 0.002AER, mg/24 h \>30111691.9271.780, 3.064*P* = 0.009Haemoglobin, g/l\<903380.2890.089, 0.811*P* = 0.012HbA~1c~, % \>6.0242131.8281.358, 3.298*P* = 0.001[^9][^10][^11]

Discussion {#sec12-0300060515593765}
==========

The present study showed that 25(OH)D levels were lower in patients with diabetic nephropathy than in healthy controls, and tended to decrease with diabetic nephropathy stage. Calcitriol or 1, 25(OH) vitamin D is a steroid hormone that has genomic and nongenomic effects. Calcitriol expresses these functions by the ubiquitous existence of a vitamin D receptor in the body, such as in endothelial cells and vascular smooth muscle cells.^[@bibr18-0300060515593765]^ In the present study, 25(OH)D was used as a sensitive marker of total body vitamin D storage. Extra-renal 1α-hydroxylase is known to be expressed outside the kidney,^[@bibr19-0300060515593765]^ and the half-life of 25(OH)D is ∼3 weeks,^[@bibr20-0300060515593765]^ which is longer than that of calcitriol. Thus, 25(OH)D is a convenient and sensitive molecule for testing vitamin D levels.

In the present study, AER was determined to be an independent risk factor of 25(OH)D deficiency. Serum 25(OH)D levels were negatively associated with AER, which is not only the primary sign of kidney disease severity but also a marker of diabetic nephropathy progression. Vitamin D deficiency was associated with an increased risk of albuminuria and renal failure in the Third Health and Nutrition Examination Survey (NHANES III) cohort.^[@bibr21-0300060515593765]^ In patients with chronic kidney disease and vitamin D deficiency, urine protein levels can be decreased, and renal function can be improved to some extent, with regular vitamin D supplementation.^[@bibr5-0300060515593765]^ The present study found that the 25(OH)D level was positively associated with the serum albumin level. Serum 25(OH)D is known to bind proteins such as the D-binding protein and albumin in blood to perform its function.^[@bibr22-0300060515593765]^ Lost urinary microalbumin can decrease the serum albumin level, which explains the decrease in protein synthesis and the large loss in urinary albumin that affects serum 25(OH)D concentration.

After controlling for seasonal affects on vitamin D (i.e., the present study was conducted during the summer), serum 25(OH)D levels were found to be significantly associated with age, sex, and BMI. In addition, a higher proportion of older, female and obese patients with low 25(OH)D levels was observed. Progression of diabetic nephropathy, enzyme activity reduction, gut dysfunction, low vitamin D absorption from the diet, oestrogen decrease in older female patients, and lack of UVB radiation are all thought to contribute to low 25(OH)D levels.^[@bibr23-0300060515593765]^ Many studies conducted in the general population have shown a high prevalence of vitamin D deficiency in obese subjects.^[@bibr24-0300060515593765]^

In the present study, the serum 25(OH)D level was negatively correlated with with fasting blood glucose and HbA~1c~; in addition, HbA~1c~ was shown to be an independent risk factor of 25(OH)D deficiency. Vitamin D is thought to be involved in the pathophysiology of insulin resistance, insulin sensibility, and β-cell function.^[@bibr25-0300060515593765]^ The direct effect of vitamin D can be mediated through binding of its circulating active form (i.e., 1, 25-\[OH\]~2~D) to β-cell receptors. Indirect effects of vitamin D are mediated by its important and classical role in regulating extracellular calcium and calcium channels through β-cells, because insulin secretion is a calcium-dependent process.^[@bibr18-0300060515593765]^

The present study showed that vitamin D deficiency was associated with proliferative diabetic retinopathy. Diabetic retinopathy is a microvascular complication of diabetes mellitus that shares similar pathophysiological features with diabetic nephropathy. Retinal involvement exists in most cases of diabetic nephropathy.^[@bibr26-0300060515593765]^ Microalbuminuria has been suggested to significantly increase the risk of development and progression of diabetic retinopathy in patients with type 2 diabetes, even after adjustment for diabetes duration.^[@bibr27-0300060515593765]^ Vitamin D receptors are present in the human retina, and vitamin D deficiency is related to retinopathy risk in diabetes.^[@bibr28-0300060515593765]^ Molecular research has shown that the Fok-1 single nucleotide polymorphism of the vitamin D (1,25- dihydroxyvitamin D3) receptor (*VDR*) gene is associated with increased transcriptional activity of *VDR* and less-severe (nonproliferative) diabetic retinopathy.^[@bibr29-0300060515593765]^

The results of the present study are limited by several factors: First, the sample size was relatively small; Secondly, residual confounding factors related to vitamin D deficiency, such as lifestyle, were not ruled out during this study, although the statistical analysis was carefully adjusted; Thirdly, the dietary intake of vitamin D was ascertained by a 24 h diet recall (which has a recall bias); finally, the diabetic nephropathy diagnosis in the present study was based on clinical diagnosis, and no renal biopsy, renal ultrasound, or emission computed tomography tests were performed.

In conclusion, 25(OH)D deficiency is prevalent among nondialysed patients with diabetic nephropathy and tends to decrease with diabetic nephropathy stage. Age, obesity, glucose level, and renal function are independent risk factors for 25(OH)D deficiency, and serum 25(OH)D appears to be a favourable inverse predicator of diabetic nephropathy progression.
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[^4]: *P* \< 0.05 versus controls; ^\#^*P* \< 0.05 versus diabetic nephropathy I/II; ^Δ^*P* \< 0.05 versus diabetic nephropathy III; ^&^*P* \< 0.05 versus diabetic nephropathy IV (all one-way analysis of variance).

[^5]: Data presented as *n* prevalence.

[^6]: Healthy control data were included in this subgroup.

[^7]: Ref, reference group; BMI, body mass index; WHR, waist hip ratio; SBP, systolic blood pressure; AER, albumin excretion rate; eGFR, estimated glomerular filtration rate; HbA~1c~, glycosylated haemoglobin; Ccr, creatinine clearance rate; BUN, blood urea nitrogen; HDL, high-density lipoprotein; LDL, low-density lipoprotein; DRP, diabetic retinopathy; DNP, diabetic neuropathy.

[^8]: NS, no statistically significant difference (*P* \> 0.05; univariate conditional logistic regression).

[^9]: Data presented as *n* prevalence.

[^10]: Dependent variables, 25(OH)D \< 15 ng/ml.

[^11]: OR, odds ratio; CI, confidence interval; BMI, body mass index; AER, albumin excretion rate; HbA~1c~, glycosylated haemoglobin.
